---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-23-000061"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2023-07-26T23:59:59+00:00"
generated_at: "2026-06-13T02:23:33.316963+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech expands to oncology; FDA accepts IND for KB707 for solid tumors

## Summary
- FDA accepted IND for KB707, a modified HSV-1 vector delivering IL-12 and IL-2 for solid tumors.
- Two formulations: intratumoral injection for accessible tumors and inhaled (nebulized) for lung delivery.
- Phase 1 Opal 1 study to start 2H 2023; amendment for inhaled formulation expected in 2H 2023.
- Preclinical data showed antitumor responses in checkpoint-inhibitor-refractory mouse models.
- Investor conference call on July 27, 2023 at 8:00 AM ET to discuss KB707 program.

## SEC filing metadata
- accession: 0001711279-23-000061
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2023-07-26T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000061/0001711279-23-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000061/krys-20230726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-23-000061
- JSON: https://secwatch.observer/filing/0001711279-23-000061.json
- Plain text: https://secwatch.observer/filing/0001711279-23-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.